Symptom management of multiple sclerosis in adults
- Michael J Olek, DO
Michael J Olek, DO
- Associate Professor of Neurology
- Loma Linda University Medical Center
- Ram N Narayan, MD
Ram N Narayan, MD
- Neuroimmunology and Neuroinfectious Disease Fellow
- University of Texas Southwestern Medical Center
- Johns Hopkins School of Medicine
- National Institutes of Health
- Elliot M Frohman, MD, PhD
Elliot M Frohman, MD, PhD
- Professor of Neurology
- University of Texas Southwestern Medical Center
- Teresa C Frohman, PA-C
Teresa C Frohman, PA-C
- MS Clinical Specialist
- UTSW Medical Center
Multiple sclerosis (MS) is an immune-mediated, inflammatory, neurodegenerative disease of the central nervous system that is a leading cause of disability in young adults.
A range of symptomatic problems can occur in patients with MS. Cognitive dysfunction, depression, fatigue, and gait impairment are increasingly common with disease progression. Spasticity, tremor, seizures, sphincter dysfunction, and sexual dysfunction may also complicate disease progression.
Management of the comorbid problems associated with MS will be reviewed here. Other aspects of MS management are discussed separately. (See "Treatment of acute exacerbations of multiple sclerosis in adults" and "Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults" and "Treatment of progressive multiple sclerosis in adults".)
Common symptoms of bladder dysfunction in patients with MS include urinary frequency, urgency, and nocturia. Urinary tract infections are also common in MS, particularly in women, and may increase the extent of bladder dysfunction . (See "Clinical features of multiple sclerosis in adults", section on 'Bowel and bladder dysfunction'.)
Our approach in evaluating a patient with urinary symptoms involves the following steps:
- Phé V, Pakzad M, Curtis C, et al. Urinary tract infections in multiple sclerosis. Mult Scler 2016; 22:855.
- Kragt JJ, Hoogervorst EL, Uitdehaag BM, Polman CH. Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis. Neurology 2004; 63:1716.
- Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80:470.
- Yang CC. Bladder management in multiple sclerosis. Phys Med Rehabil Clin N Am 2013; 24:673.
- Frohman TC, Castro W, Shah A, et al. Symptomatic therapy in multiple sclerosis. Ther Adv Neurol Disord 2011; 4:83.
- Goessaert AS, Everaert KC. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. Expert Rev Neurother 2012; 12:763.
- Chancellor MB, Patel V, Leng WW, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology 2013; 81:841.
- Soljanik I. Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review. Drugs 2013; 73:1055.
- Fjorback MV, Rijkhoff N, Petersen T, et al. Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn 2006; 25:349.
- Kabay S, Kabay SC, Yucel M, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn 2009; 28:964.
- Bosma R, Wynia K, Havlíková E, et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005; 112:1.
- Reynard JM, Cannon A, Yang Q, Abrams P. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998; 81:215.
- DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003; 63:153.
- He D, Zhang Y, Dong S, et al. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database Syst Rev 2013; :CD008876.
- Patti F. Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs 2012; 21:1679.
- Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63:1579.
- Shaygannejad V, Janghorbani M, Ashtari F, et al. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci 2008; 35:476.
- Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011; 76:1500.
- Pepping M, Ehde DM. Neuropsychological evaluation and treatment of multiple sclerosis: the importance of a neuro-rehabilitation focus. Phys Med Rehabil Clin N Am 2005; 16:411.
- Filippi M, Rocca MA. Let's rehabilitate cognitive rehabilitation in multiple sclerosis. Neurology 2013; 81:2060.
- Rosti-Otajärvi EM, Hämäläinen PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev 2011; :CD009131.
- Chiaravalloti ND, Moore NB, Nikelshpur OM, DeLuca J. An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial. Neurology 2013; 81:2066.
- Koch MW, Glazenborg A, Uyttenboogaart M, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev 2011; :CD007295.
- Hind D, Cotter J, Thake A, et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry 2014; 14:5.
- Feinstein A, Rector N, Motl R. Exercising away the blues: can it help multiple sclerosis-related depression? Mult Scler 2013; 19:1815.
- Frohman AN, Okuda DT, Beh S, et al. Aquatic training in MS: neurotherapeutic impact upon quality of life. Ann Clin Transl Neurol 2015; 2:864.
- Feinstein A. Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Mult Scler 2000; 6:343.
- Pucci E, Branãs P, D'Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007; :CD002818.
- Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72:179.
- Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol 2009; 256:645.
- Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005; 64:1139.
- Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005; 64:1267.
- Tejani AM, Wasdell M, Spiwak R, et al. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2012; :CD007280.
- Ledinek AH, Sajko MC, Rot U. Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. Clin Neurol Neurosurg 2013; 115 Suppl 1:S86.
- Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int 2014; 2014:798285.
- Haselkorn JK, Hughes C, Rae-Grant A, et al. Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2015; 85:1896.
- Bethoux F. Gait disorders in multiple sclerosis. Continuum (Minneap Minn) 2013; 19:1007.
- Barrett CL, Mann GE, Taylor PN, Strike P. A randomized trial to investigate the effects of functional electrical stimulation and therapeutic exercise on walking performance for people with multiple sclerosis. Mult Scler 2009; 15:493.
- Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373:732.
- Safety and efficacy study of oral fampridine-SR in patients with multiple sclerosis. http://clinicaltrials.gov/show/NCT00053417 (Accessed on November 19, 2014).
- Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68:494.
- Thompson A, Polman C. Improving function: a new treatment era for multiple sclerosis? Lancet 2009; 373:697.
- Raffel JB, Malik O, Nicholas RS. Assessing dalfampridine efficacy in the physician's office. Mult Scler 2014; 20:24.
- Lugaresi A. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis. Expert Opin Drug Metab Toxicol 2015; 11:295.
- Birnbaum G, Iverson J. Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis. Neurology 2014; 83:1610.
- Davis SL, Wilson TE, White AT, Frohman EM. Thermoregulation in multiple sclerosis. J Appl Physiol (1985) 2010; 109:1531.
- van Diemen HA, van Dongen MM, Dammers JW, Polman CH. Increased visual impairment after exercise (Uhthoff's phenomenon) in multiple sclerosis: therapeutic possibilities. Eur Neurol 1992; 32:231.
- Rae-Grant AD. Unusual symptoms and syndromes in multiple sclerosis. Continuum (Minneap Minn) 2013; 19:992.
- Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999; 162:162.
- Nyquist PA, Cascino GD, Rodriguez M. Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minn, 1990-1998. Mayo Clin Proc 2001; 76:983.
- Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol 1999; 161:743.
- Fowler CJ, Miller JR, Sharief MK, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:700.
- Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol 2009; 181:252.
- Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004; 171:1189.
- Trojan DA, Da Costa D, Bar-Or A, et al. Sleep abnormalities in multiple sclerosis patients. Mult Scler 2008; 14:S160.
- Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28:140.
- Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016; 86:1818.
- Amatya B, Khan F, La Mantia L, et al. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev 2013; :CD009974.
- Tassorelli C, Bergamaschi R, Buscone S, et al. Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurol Sci 2008; 29 Suppl 4:S360.
- Tzelepis GE, McCool FD. Respiratory dysfunction in multiple sclerosis. Respir Med 2015; 109:671.
- Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011; 77:1611.
- Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012; 18:1144.
- Bhargava P, Cassard S, Steele SU, et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials 2014; 39:288.
- Alharbi FM. Update in vitamin D and multiple sclerosis. Neurosciences (Riyadh) 2015; 20:329.
- Mesliniene S, Ramrattan L, Giddings S, Sheikh-Ali M. Role of vitamin D in the onset, progression, and severity of multiple sclerosis. Endocr Pract 2013; 19:129.
- Sotirchos ES, Bhargava P, Eckstein C, et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology 2016; 86:382.
- Olsen SA. A review of complementary and alternative medicine (CAM) by people with multiple sclerosis. Occup Ther Int 2009; 16:57.
- Yadav V, Bourdette D. Complementary and alternative medicine: is there a role in multiple sclerosis? Curr Neurol Neurosci Rep 2006; 6:259.
- Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004; 62:2058.
- Apel A, Greim B, König N, Zettl UK. Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis. J Neurol 2006; 253:1331.
- Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 2010; 75:1141.
- Tavee J, Stone L. Healing the mind: meditation and multiple sclerosis. Neurology 2010; 75:1130.
- Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70:174.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 2015; 313:2456.
- Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013; 260:984.
- Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 2013; 12:857.
- Zajicek JP, Hobart JC, Slade A, et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012; 83:1125.
- BLADDER DYSFUNCTION
- BOWEL DYSFUNCTION
- COGNITIVE IMPAIRMENT
- Pharmacologic treatment
- Nonpharmacologic approaches
- GAIT IMPAIRMENT
- HEAT INTOLERANCE
- PAROXYSMAL SYMPTOMS
- SEXUAL DYSFUNCTION
- SPEECH, SWALLOW, AND RESPIRATORY FUNCTION
- VISUAL SYSTEM DISTURBANCES
- VITAMIN D
- COMPLEMENTARY AND ALTERNATIVE MEDICINE
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS